{"id":"W2952953974","doi":"10.1016/j.jtho.2019.06.010","title":"Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Foundation Medicine; EMD Serono; Eisai; Daiichi-Sankyo; Pfizer; Incyte; Genentech; IFM Therapeutics; Horizon Pharma; Exelixis; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Roche; Celgene; Novartis; AbbVie; MedImmune; Merck; Boehringer Ingelheim; Amgen; PharmaMar; Daiichi Sankyo Europe; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Common Terminology Criteria for Adverse Events; Tolerability; Adverse effect; Internal medicine; Oncology; Cohort; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088735,0.0001111476,0.0008466617,0.0001469905,0.00001288982,0.000004502345,0.00009515956,0.0001614355,0.0001019303],"category_scores_gemma":[0.00009648885,0.00007666094,0.000150284,0.0001456205,0.0001590485,0.0001475562,0.00004227351,0.0003859138,0.000001652427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001883751,"about_ca_system_score_gemma":0.0003591995,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001016049,"about_ca_topic_score_gemma":0.00007485788,"domain_scores_codex":[0.9984599,0.0002297424,0.0007337885,0.0001594346,0.0002590976,0.0001579727],"domain_scores_gemma":[0.9985116,0.0002460304,0.0007348829,0.000194821,0.0002222985,0.00009032917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05794882,0.0007252144,0.5836111,0.00008254353,0.0001111456,0.00002115917,0.00007874986,7.890966e-7,0.0009154579,4.458217e-7,0.00001708533,0.3564875],"study_design_scores_gemma":[0.0148105,0.01478837,0.9688914,0.0004034459,0.0001105973,0.00008969372,0.0000400314,0.000004166111,0.0004270647,0.00001318495,0.0003459521,0.00007552023],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976431,0.0002744953,0.00001908454,0.0006023207,0.0007166574,0.0003608277,0.000002446886,0.000003105266,0.000378029],"genre_scores_gemma":[0.9989452,0.0001547202,0.0005091933,0.0001654088,0.00005946781,0.000001469999,0.000001318194,0.00001147313,0.0001517013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3852804,"threshold_uncertainty_score":0.3126143,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02307603620406029,"score_gpt":0.4132323152498739,"score_spread":0.3901562790458136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}